These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Efficacy and Safety of Topical Sirolimus Therapy for Facial Angiofibromas in the Tuberous Sclerosis Complex : A Randomized Clinical Trial. Wataya-Kaneda M, Nakamura A, Tanaka M, Hayashi M, Matsumoto S, Yamamoto K, Katayama I. JAMA Dermatol; 2017 Jan 01; 153(1):39-48. PubMed ID: 27837201 [Abstract] [Full Text] [Related]
4. Comparative Effects of Topical 0.2% Sirolimus for Angiofibromas in Adults and Pediatric Patients with Tuberous Sclerosis Complex. Lee YI, Lee JH, Kim DY, Chung KY, Shin JU. Dermatology; 2018 Jan 01; 234(1-2):13-22. PubMed ID: 29925060 [Abstract] [Full Text] [Related]
16. [Facial angiofibromas associated to tuberous sclerosis treated with topical sirolimus]. Tiedemann Svendsen M, Bygum A, Hansen LK, Broesby-Olsen S. Ugeskr Laeger; 2013 Oct 21; 175(43):2569-70. PubMed ID: 24629155 [Abstract] [Full Text] [Related]
17. Topical everolimus for facial angiofibromas in the tuberous sclerosis complex. A first case report. Dill PE, De Bernardis G, Weber P, Lösch U. Pediatr Neurol; 2014 Jul 21; 51(1):109-13. PubMed ID: 24810875 [Abstract] [Full Text] [Related]